Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  American Journal of Physiology. Heart and Circulatory Physiology

• Publication date

  2005-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1152/AJPHEART.01186.2004PMID 15894569
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ACE2 gene expression is up-regulated in the human failing heart

  2004cited by this paper
• Effect of the renin-angiotensinaldosterone system on the cardiac interstium in heart failure

  2004cited by this paper
• Upregulation of Angiotensin-Converting Enzyme 2 After Myocardial Infarction by Blockade of Angiotensin II Receptors

  2004cited by this paper
• Inhibitory Effect of Natriuretic Peptides on Aldosterone Synthase Gene Expression in Cultured Neonatal Rat Cardiocytes

  2003cited by this paper
• EPLERENONE POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE EFFICACY AND SURVIVAL STUDY INVESTIGATORS. EPLERENONE, A SELECTIVE ALDOSTERONE BLOCKER, IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION

  2003cited by this paper
• Immediate Administration of Mineralocorticoid Receptor Antagonist Spironolactone Prevents Post-Infarct Left Ventricular Remodeling Associated With Suppression of a Marker of Myocardial Collagen Synthesis in Patients With First Anterior Acute Myocardial Infarction

  2003cited by this paper
• Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

  2003cited by this paper
• Novel Peptide Inhibitors of Angiotensin-converting Enzyme 2*

  2003cited by this paper
• Increased susceptibility of hypertrophied hearts to ischemic injury.

  2003cited by this paper
• Effects of the AT1‐receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure

  2003cited by this paper
• The role of ACE2 in cardiovascular physiology.

  2003cited by this paper
• Increased Angiotensin-(1-7)–Forming Activity in Failing Human Heart Ventricles: Evidence for Upregulation of the Angiotensin-Converting Enzyme Homologue ACE2

  2003cited by this paper
• Heart failure.

  2003cited by this paper
• Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins.

  2003cited by this paper
• Heart failure: a hemodynamic disorder complicated by maladaptive proliferative responses

  2003cited by this paper
• Effects of Long-Term Monotherapy With Eplerenone, a Novel Aldosterone Blocker, on Progression of Left Ventricular Dysfunction and Remodeling in Dogs With Heart Failure

  2002cited by this paper
• Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression.

  2002cited by this paper
• Angiotensin-converting enzyme 2 is an essential regulator of heart function

  2002cited by this paper
• Temporal changes in natriuretic and antinatriuretic systems after closure of a large arteriovenous fistula.

  2001cited by this paper
• Aldosterone Induces Angiotensin-Converting-Enzyme Gene Expression in Cultured Neonatal Rat Cardiocytes

  2001cited by this paper
• Effect of a selective aldosterone receptor antagonist in myocardial infarction.

  2001cited by this paper
• Aldosterone Production Is Activated in Failing Ventricle in Humans

  2001cited by this paper
• Vascular gp91(phox): beyond the endothelium.

  2000cited by this paper
• A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9

  2000cited by this paper
• Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure: Insights From the Randomized Aldactone Evaluation Study (RALES)

  2000cited by this paper
• Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure.

  2000cited by this paper
• Fibrosis and hypertensive heart disease

  2000cited by this paper
• The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

  2000cited by this paper
• The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  1999cited by this paper
• Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure.

  1998cited by this paper
• Myocardial Production of Aldosterone and Corticosterone in the Rat

  1998cited by this paper
• Effect of the renin-angiotensin-aldosterone system on the cardiac interstitium in heart failure.

  1996cited by this paper
• Effects of angiotensin II and aldosterone on collagen gene expression and protein turnover in cardiac fibroblasts

  1996cited by this paper
• High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes.

  1996cited by this paper
• Expression of renin-angiotensin system components in the heart, kidneys, and lungs of rats with experimental heart failure.

  1995cited by this paper
• Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone.

  1994cited by this paper
• Structural remodeling in hypertensive heart disease and the role of hormones.

  1994cited by this paper
• Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism.

  1993cited by this paper
• The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure.

  1992cited by this paper
• Pathological Hypertrophy and Cardiac Interstitium: Fibrosis and Renin‐Angiotensin‐Aldosterone System

  1991cited by this paper
• Remodeling of the rat right and left ventricles in experimental hypertension.

  1990cited by this paper
• Effect of converting-enzyme inhibition on renal response to ANF in rats with experimental heart failure.

  1990cited by this paper
• Hormonal determinants of sodium excretion in rats with experimental high-output heart failure.

  1988cited by this paper
• Renal and circulatory mechanisms in congestive heart failure.

  1987cited by this paper
• The neurohumoral axis in congestive heart failure.

  1984influential reference
• Direct spectrophotometric assay for angiotensin-converting enzyme in serum.

  1983cited by this paper
• Mechanism of sodium and water retention in rats with experimental heart failure.

  1973cited by this paper
• Heart Failure

  1937cited by this paper
• Some histological methods: Trichrome staining and their preliminary technique

  year unknowninfluential reference

• ACE Inhibitor/ARB Therapy and Other Risk Factors for COVID-19 Infection in Elderly Hypertensive Patients: Sub-Group Analysis Based on a Single-Center, Retrospective, Observational Study in Japan.

  2026cites this paper
• ACE2 gene transgenesis enhances memory of psychophysiological trauma in mouse models of post-traumatic stress disorder

  2025cites this paper
• Anti-Fibrotic Potential of Angiotensin (1-7) in Hemodynamically Overloaded Rat Heart

  2023cites this paper
• COVID-19 Therapeutics Why Not Angiotensin Receptor Blockers (ARBs)?

  2023cites this paper
• Increased glucocorticoid metabolism in diabetic kidney disease

  2022cites this paper
• The prevalence and course of COVID-19 and the Cardiovascular Diseases

  2022cites this paper
• Soluble ACE2 and angiotensin II levels are modulated in hypertensive COVID-19 patients treated with different antihypertension drugs

  2022cites this paper
• Sex Difference in MasR Expression and Functions in the Renal System

  2022cites this paper
• Renin Angiotensin System Blockers and Risk of Mortality in Hypertensive Patients Hospitalized for COVID-19: An Italian Registry

  2022cites this paper
• Overexpression of angiotensin-converting enzyme 2 by renin-angiotensin system inhibitors. Truth or myth? A systematic review of animal studies

  2021cites this paper
• Pulmonary, cardiac and renal distribution of ACE2, furin, TMPRSS2 and ADAM17 in rats with heart failure: Potential implication for COVID‐19 disease

  2021cites this paper
• Controversial Roles of the Renin Angiotensin System and Its Modulators During the COVID-19 Pandemic

  2021cites this paper
• CT visual quantitative evaluation of hypertensive patients with coronavirus disease (COVID-19): Potential influence of angiotensin converting enzyme inhibitors / angiotensin receptor blockers on severity of lung involvement

  2021cites this paper
• SARS–CoV-2 Mediated Hyperferritinemia and Cardiac Arrest: Preliminary Insights

  2021cites this paper
• A pressor dose of angiotensin II has no influence on the angiotensin‐converting enzyme 2 and other molecules associated with SARS‐CoV‐2 infection in mice

  2021cites this paper
• Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19

  2021cites this paper
• Increased complications of COVID-19 in people with cardiovascular disease: Role of the renin–angiotensin-aldosterone system (RAAS) dysregulation

  2021cites this paper
• Pharmacotherapy for hypertensive urgency and emergency in COVID-19 patients

  2021cites this paper
• The pivotal link between ACE2 deficiency and SARS-CoV-2 infection: One year later

  2021cites this paper
• Renin–angiotensin–aldosterone system inhibitors and SARS-CoV-2 infection: an analysis from the veteran's affairs healthcare system

  2021cites this paper
• Role of ACE2 polymorphism in COVID-19: impact of age

  2021cites this paper
• The Effect of Chronic and Inhospital Exposure to Renin-Angiotensin System Inhibitors on the Outcome and Inflammatory State of Coronavirus Disease 2019 Adult Inpatients

  2021cites this paper
• Management of COVID-19 in cancer patients receiving cardiotoxic anti-cancer therapy. Future recommendations for cardio-oncology

  2021cites this paper
• Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2

  2020cites this paper
• Covid-19 infection and mortality: a physiologist’s perspective enlightening clinical features and plausible interventional strategies

  2020cites this paper
• Angiotensin converting enzyme 2 - An ally or a Trojan horse? Implications to SARS-CoV-2 -related cardiovascular complications.

  2020cites this paper
• COVID-19, ACE2, and the cardiovascular consequences

  2020cites this paper
• Coronavirus Disease 2019 (COVID‐19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection

  2020cites this paper
• COVID‐19: Risk groups, mechanistic insights and challenges

  2020cites this paper
• Might renin–angiotensin system blockers play a role in the COVID-19 pandemic?

  2020cites this paper
• Hypertension, the renin–angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19

  2020cites this paper
• Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2

  2020cites this paper
• Current status of potential therapeutic candidates for the COVID-19 crisis

  2020cites this paper
• SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications

  2020cites this paper
• Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcome of COVID-19 : A Systematic Review and Meta-analysis

  2020cites this paper
• La práctica de la Cardiología ante la pandemia por COVID-19. Recomendaciones de la comunidad cardiológica mexicana

  2020cites this paper
• Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy.

  2020cites this paper
• Angiotensin converting enzyme 2 at the interface between renin‐angiotensin system inhibition and coronavirus disease 2019

  2020cites this paper
• Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19

  2020cites this paper
• Clinical Outcomes From COVID-19 Following Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers Among Patients with Hypertension in South Korea: A nationwide study

  2020cites this paper
• Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science

  2020cites this paper
• Renin-angiotensin system blockers and severe acute respiratory syndrome coronavirus 2

  2020cites this paper
• COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.

  2020cites this paper
• Renin-angiotensin-system inhibition in the context of corona virus disease-19: experimental evidence, observational studies, and clinical implications

  2020cites this paper
• The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2

  2020cites this paper
• Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator

  2020cites this paper
• Double trouble: combined cardiovascular effects of particulate matter exposure and coronavirus disease 2019

  2020cites this paper
• Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Mortality Among COVID-19 Patients: A Systematic Review and Meta-Analysis

  2020cites this paper
• A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor

  2020cites this paper
• COVID-19 and the renin, angiotensin, aldosterone system. A complex relationship.

  2020cites this paper
• Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: a nationwide study

  2020cites this paper
• COVID-19 and acute kidney injury.

  2020cites this paper
• Both aldosterone and spironolactone can modulate the intracellular ACE/ANG II/AT1 and ACE2/ANG (1‐7)/MAS receptor axes in human mesangial cells

  2019cites this paper
• Rosiglitazone treatment restores renal responsiveness to atrial natriuretic peptide in rats with congestive heart failure

  2019cites this paper
• Effects of Testosterone on Analgesia in Formalin-Treated Mice

  2018cites this paper
• Effect of the renal natriuretic peptide, ularitide, alone or combined with Vasopeptidase inhibitor, Omapatrilat, on experimental volume overload-induced congestive heart failure in rats (Ularitide/Omapatrilat in Congestive Heart Failure)

  2017cites this paper
• Effect of the renal natriuretic peptide, ularitide, alone or combined with Vasopeptidase inhibitor, Omapatrilat, on experimental volume overload-induced congestive heart failure in rats (Ularitide/Omapatrilat in Congestive Heart Failure)

  2017cites this paper
• Angiotensin II control of regional haemodynamics in rats with aortocaval fistula

  2016cites this paper
• Activation of renin–angiotensin–aldosterone system (RAAS) in the lung of smoking-induced pulmonary arterial hypertension (PAH) rats

  2015cites this paper
• ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension

  2015cites this paper
• Cardiac Adaptation to Volume Overload

  2013cites this paper
• Aldosterone induces electrical remodeling independent of hypertension.

  2013cites this paper
• Lack of efficacy of low-dose spironolactone as adjunct treatment to conventional congestive heart failure treatment in dogs.

  2011cites this paper
• Aortocaval Fistula in Rat: A Unique Model of Volume-Overload Congestive Heart Failure and Cardiac Hypertrophy

  2011cites this paper
• Targeting the ACE2-Ang-(1-7) pathway in cardiac fibroblasts to treat cardiac remodeling and heart failure.

  2011influential citation
• Prognostic value of plasma renin activity in heart failure.

  2011cites this paper
• Angiotensin-converting enzymes and drug discovery in cardiovascular diseases.

  2010cites this paper
• The usefulness of chronic heart failure treatments in chronic cardiac graft failure.

  2010cites this paper
• Regulation of placental growth by aldosterone and cortisol.

  2010cites this paper
• Losartan attenuates chronic cigarette smoke exposure-induced pulmonary arterial hypertension in rats: Possible involvement of angiotensin-converting enzyme-2

  2010cites this paper
• Effect of canrenone and amiloride on the prooxidative effect induced by aldosterone in human mononuclear leukocytes in vitro

  2009cites this paper
• Dietary salt restriction activates mineralocorticoid receptor signaling in volume-overloaded heart failure.

  2009cites this paper
• Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone.

  2008cites this paper
• Aldosterone, but not angiotensin II, reduces angiotensin converting enzyme 2 gene expression levels in cultured neonatal rat cardiomyocytes.

  2008cites this paper
• Angiotensin II: a hormone involved in and contributing to pro-hypertrophic cardiac networks and target of anti-hypertrophic cross-talks.

  2008cites this paper
• Angiotensin‐converting enzyme 2 in the brain: properties and future directions

  2008cites this paper
• The Effect of Spironolactone on Concentration of LH, FSH, Testosterone Di-hydrotestosterone and Spermatogenesis in Rats

  2007cites this paper
• The emerging role of ACE2 in physiology and disease†

  2007cites this paper
• Effects of treatment with a 5‐HT4 receptor antagonist in heart failure

  2007cites this paper
• بررسی تاثیر داروی اسپیرنولاکتون بر میزان هورمون هایLH، FSH، تستوسترون، دی هیدرو تستوسترون و اسپرماتوژنزدر موش صحرایی

  2007cites this paper
• The two fACEs of the tissue renin-angiotensin systems: implication in cardiovascular diseases.

  2007cites this paper
• I homóloga) en el remodelamiento y disfunción ventricular temprano y tardío post infarto del miocardio en la rata

  2006cites this paper
• Aldosterone antagonism improves endothelial-dependent vasorelaxation in heart failure via upregulation of endothelial nitric oxide synthase production.

  2006cites this paper
• Cardioprotective role for angiotensin-(1-7) and angiotensin converting enzyme 2 in the heart.

  2006cites this paper